Shares of Hyperion Therapeutics soared nearly 20% today after receiving notice that the Food and Drug Administration would not meets its January PDUFA date for Ravicti. However, the reasons for the UCD drug's delay have the bulls out in full force. Watch as Motley Fool health care analyst David Williamson explains what has investors so excited and what it means for Hyperion.
Ravicti gets a 3 month delay and shares pop
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid